HempFusion Announces Inclusion in Leading Cannabis ETFs
January 26 2021 - 7:05AM
Business Wire
HempFusion Wellness Inc. (TSX:CBD.U) (FWB:8OO)
(“HempFusion” or the “Company”) is pleased to
announce that it has been included in two leading cannabis &
hemp-derived CBD focused exchange-traded funds (“ETFs”),
AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) and
AdvisorShares Pure Cannabis ETF (NYSE:YOLO).
AdvisorShares is a leading sponsor of actively managed ETFs.
Pure US Cannabis ETF (MSOS) is the only US-listed ETF dedicated
solely to US cannabis exposure, with over US$616,000,000 in assets
under management (“AUM”). Pure Cannabis ETF (YOLO) was the
first US-based actively managed ETF focused on the global cannabis
industry. YOLO and MSOS endeavor to achieve long-term capital
growth by investing in some of the largest foreign and domestic
cannabis and hemp-derived CBD companies. The two AdvisorShares ETFs
have a combined AUM of over US$880,000,000 as of January 22,
2021.
“We are pleased the AdvisorShares ETFs have initiated positions
in our Company. This represents a strong milestone for the Company
and provides us added exposure to the investment community,”
commented Jason Mitchell, N.D., HempFusion’s co-founder and CEO.
“Inclusion in these ETFs brings additional exposure to potential
new investors as well as generates value for existing shareholders.
With our listing on the TSX, current market capitalization, and
liquidity, we believe we now meet many cannabis-related ETFs’
inclusion requirements, and we look forward to other potential
ETFs’ initiating positions.”
ABOUT HEMPFUSION
HempFusion is a leading health and wellness CBD company
utilizing the power of whole-food hemp nutrition. HempFusion
distributes its family of brands, including HempFusion, Probulin
Probiotics, Biome Research, and HF Labs, to approximately 4,000
retail locations across all 50 states of the United States and
select international locations. Built on a foundation of regulatory
compliance and human safety, HempFusion’s diverse product portfolio
comprises 46 SKUs including tinctures, proprietary FDA Drug Listed
Over-The-Counter (OTC) Topicals, Doctor/Practitioner Lines and
more. With a strong focus on research and development, HempFusion
has an additional 30 products under development. HempFusion is a
board member of the US Hemp Roundtable, and HempFusion’s
wholly-owned subsidiary, Probulin Probiotics, is one of the
fastest-growing probiotics companies in the United States,
according to SPINs reported data. HempFusion’s CBD products are
based on a proprietary Whole Food Hemp Complex™ and are available
in-store or by visiting HempFusion online at www.hempfusion.com or
www.probulin.com.
Follow HempFusion on Twitter, Facebook and Instagram and
Probulin on Twitter, Facebook and Instagram.
FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements and
forward-looking information within the meaning of Canadian
securities legislation (collectively, “forward-looking
statements“) that relate to HempFusion’s current expectations
and views of future events. Any statements that express, or involve
discussions as to, expectations, beliefs, plans, objectives,
assumptions or future events or performance (often, but not always,
through the use of words or phrases such as “will likely result”,
“are expected to”, “expects”, “will continue”, “is anticipated”,
“anticipates”, “believes”, “estimated”, “intends”, “plans”,
“forecast”, “projection”, “strategy”, “objective” and “outlook”)
are not historical facts and may be forward-looking statements and
may involve estimates, assumptions and uncertainties which could
cause actual results or outcomes to differ materially from those
expressed in such forward-looking statements. No assurance can be
given that these expectations will prove to be correct and such
forward-looking statements included in this news release should not
be unduly relied upon. These statements speak only as of the date
of this news release. In particular and without limitation, this
news release contains forward-looking statements relating to
meeting the inclusion requirements of or inclusion in other
cannabis-related ETFs and the Company’s other plans, focus and
objectives.
Forward-looking statements are based on a number of assumptions
and are subject to a number of risks and uncertainties, many of
which are beyond HempFusion’s control, which could cause actual
results and events to differ materially from those that are
disclosed in or implied by such forward-looking statements. Such
risks and uncertainties include, but are not limited to, the impact
and progression of the COVID-19 pandemic and other factors set
forth under “Forward-Looking Statements” and “Risk Factors” in the
final long form prospectus of the Company dated December 17, 2020
and available under the Company’s profile on SEDAR at
www.sedar.com. HempFusion undertakes no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required
by law. New factors emerge from time to time, and it is not
possible for HempFusion to predict all of them or assess the impact
of each such factor or the extent to which any factor, or
combination of factors, may cause results to differ materially from
those contained in any forward-looking statement. Any
forward-looking statements contained in this news release are
expressly qualified in their entirety by this cautionary
statement.
Neither the TSX nor its Regulation Services Provider (as that
term is defined in the policies of the TSX) accepts responsibility
for the adequacy or accuracy of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126005426/en/
Jason Mitchell, N.D. Chief Executive Officer and Director Email:
ir@hempfusion.com Phone: 416-803-5638
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Mar 2024 to Apr 2024
HempFusion Wellness (TSX:CBD.U)
Historical Stock Chart
From Apr 2023 to Apr 2024